Background: An increasing number of patients are undergoing conversion surgery owing to the rising popularity of relatively strong regimens such as immune checkpoint inhibitor (ICI)-combined chemotherapy for the treatment of unresectable esophageal or esophagogastric junction (EGJ) cancer. However, the perioperative safety of conversion surgery after ICI combined with chemotherapy remains unclear. We report two cases of postoperative immune-related adverse events (irAEs) in patients who underwent conversion surgery after the induction of ICI-combined chemotherapy.
Case presentations: Case 1: A patient with unresectable EGJ adenocarcinoma and para-abdominal aortic lymph node (LN) metastasis developed adrenal insufficiency after four courses of nivolumab + S1 + oxaliplatin (Nivo+ SOX) therapy. As significant tumor shrinkage was observed, conversion surgery was performed. While the postoperative course was uneventful, two months after surgery, hypothyroidism developed and was determined to be an irAE. Thyroid hormone replacement therapy was administered and the symptoms improved. Case 2: A patient with EGJ adenocarcinoma and extensive metastasis to mediastinal, supraclavicular, and para-aortic LNs, along with aortic invasion, also received four courses of Nivo + SOX. Hypothyroidism developed during treatment and was managed with thyroid hormone replacement therapy. Following notable tumor regression, the patient underwent conversion surgery. The patient's postoperative course was uneventful and was discharged. However, one month after surgery, the patient was readmitted with severe respiratory distress and was diagnosed with interstitial pneumonia. Intensive care with extracorporeal membrane oxygenation (ECMO) was initiated following steroid and endoxan pulse therapy, but the patient died four months after surgery.
Conclusions: The risk of irAEs should always be considered in patients receiving ICIs, even after conversion surgery. This condition should be differentiated from complications of esophagectomy and managed promptly.
扫码关注我们
求助内容:
应助结果提醒方式:
